EN / 中文

About LTZ

An Immunotherapy - Focused Biotech

LTZ Therapeutics is an immunotherapy-focused biotech company pursuing the development of novel therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need. LTZ is focused on leveraging the power of innate immunity (e.g., macrophages) and elimination of immunosuppression (e.g., T regulatory cells, cancer-associated fibroblasts) as these areas have been shown to offer tremendous potential for developing innovative and effective therapies. Specifically, LTZ is developing its own novel innate engager platform to effectively activate macrophages in addition to natural killing (NK) cells as effectors to deliver direct anti-tumor and anti-immunosuppressive cell killing and promote inflammation in the tumor microenvironment – indirectly resulting in activated adaptive immunity and long-term memory.

As a global biotechnology company, we operate in both Redwood City, California, USA, and Shenzhen, China, with an experienced management team of seasoned drug developers in the USA, Germany, and China.

A global facing company with main operations in USA and China as well as a team out of Germany.

Redwood City (Bay Area), USA

Functions: discovery & research, early clinical development

Heidelberg, Germany

Functions: (reverse) translational sciences, preclinical development

Shenzhen, China

Functions: reverse translational sciences, research, preclinical development, CMC, early clinical development